0001070081-20-000057.txt : 20200207 0001070081-20-000057.hdr.sgml : 20200207 20200207164111 ACCESSION NUMBER: 0001070081-20-000057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200205 FILED AS OF DATE: 20200207 DATE AS OF CHANGE: 20200207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Almstead Neil Gregory CENTRAL INDEX KEY: 0001578850 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 20588010 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 wf-form4_158111165404736.xml FORM 4 X0306 4 2020-02-05 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578850 Almstead Neil Gregory C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Chief Technical Ops Officer Common Stock 2020-02-06 4 M 0 46898 10.85 A 73987 D Common Stock 2020-02-06 4 S 0 46898 55 D 27089 D Common Stock 2020-02-06 4 M 0 3102 10.85 A 30191 D Common Stock 2020-02-06 4 S 0 3102 55 D 27089 D Common Stock 2020-02-05 4 S 0 405 55 D 5952 I By spouse Common Stock 2020-02-06 4 S 0 4040 55 D 1912 I By spouse Stock Option (Right To Buy) 10.85 2020-02-06 4 M 0 46898 10.85 D 2023-05-15 Common Stock 46898.0 0 D Stock Option (Right To Buy) 10.85 2020-02-06 4 M 0 3102 10.85 D 2023-05-15 Common Stock 3102.0 0 D Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 216.0 216 D Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 166.0 166 D Stock Option (Right To Buy) 27.05 2024-01-27 Common Stock 40000.0 40000 D Stock Option (Right To Buy) 51.0 2025-01-01 Common Stock 69550.0 69550 D Stock Option (Right To Buy) 30.86 2026-01-03 Common Stock 55000.0 55000 D Stock Option (Right To Buy) 11.23 2027-01-02 Common Stock 35000.0 35000 D Stock Option (Right To Buy) 18.01 2028-01-02 Common Stock 70000.0 70000 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 72500.0 72500 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 17500.0 17500 D Stock Option (Right To Buy) 51.16 2030-01-28 Common Stock 69500.0 69500 D The transactions reported in this Form 4 were effected pursuant to written Rule 10b5-1 plans. Currently exercisable. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021. /s/ Avraham S. Adler, attorney-in-fact 2020-02-07